Alveo Wins XPRIZE Rapid Covid-19 Testing Competition. Click here to read the news.

It is my pleasure to announce today, May 1, 2019, that John P. DeVincenzo, M.D. is joining our Scientific Advisory Board. With more than twenty years of pathogenetic and virus research within the healthcare sector, John brings deep experience in pediatric infectious diseases.

“In this interconnected world, we are all at a high risk of catching infectious diseases,” said Ron Chiarello, PhD, CEO of Alveo. “John is going to help us take on these challenges head-on. At Alveo, we are creating a technology platform that will provide rapid, reliable, and economical cloud-based diagnostics for use by Everyone, Anytime, Everywhere™.”

“Alveo is at the forefront of overcoming limitations of current diagnostic methods,” said John P. DeVincenzo, M.D. “It is my honor to serve on the company’s Scientific Advisory Board and am thrilled to be part of a company that is creating a new ecosystem for the detection of infectious diseases.”

Currently, Dr. DeVincenzo is a Professor of Pediatrics and Professor of Molecular Sciences, Microbiology, Immunology, and Biochemistry at the University of Tennessee School of Medicine. His research has focused on understanding the pathogenesis of Respiratory Syncytial virus directly in children and using this understanding to develop therapeutic and prevention strategies against this virus. 

Dr. DeVincenzo is currently also the medical director of the University affiliated Le Bonheur Children’s Hospital Virology Laboratory and the Methodist/Le Bonheur Molecular Diagnostics Laboratory. He is the author of over 140 original published abstracts and papers on this subject. Dr. DeVincenzo’s research initially focused on the immunogenetics of RSV disease and the interplay between viral dynamics and RSV disease severity in infants. 

Subsequently, his research focus shifted to apply this knowledge of RSV dynamics to the development of novel therapeutics for RSV. The development of RNA interference-based therapeutics for RSV has taken recent priority. For his groundbreaking proof of concept work applying RNA interference concepts to develop human therapeutics, Dr. DeVincenzo’s study was listed as one of the most influential papers in medicine in 2010 (American Society for Microbiology).  

Dr. DeVincenzo received his undergraduate degree in biology from Stanford University, and then attended Vanderbilt Medical School where he became interested in pediatric infectious diseases and earned his MD degree. He is a practicing pediatric infectious disease specialist, lectures at the Medical School and is involved in award winning clinical teaching of medical students, residents, and fellows.

Over the past several months, an impressive group of seasoned leaders has joined our Board.

By Ron Chiarello, PhD, Founder and CEO of Alveo